RxDoctor Payments Data

Leonard Glade, MD

Pulmonary Disease · New Orleans, LANPI 1184676744

Payments from drug & device makers

$9,976in general payments, 2019–2025

Across 261 payments — averaging $38.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Sanofi$793
  • Regeneron Healthcare Solutions, Inc.$530
  • GSK$426
  • Boston Scientific$398
  • Abiomed$397
  • plus $2K from 37 others

What the payments were for

  • Consulting fees$4,50045%
  • Food & beverage$5,46255%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,976 in reported general payments places this provider in the 65th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$141,524
Medicare patients
385
Services billed
1,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter256$192,799
Breo ElliptaFluticasone/Vilanterol223$104,342
Dupixent PenDupilumab24$92,013
Bosentan11$85,082
EliquisApixaban106$81,368
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr153$79,377
NucalaMepolizumab15$63,753
SymbicortBudesonide/Formoterol Fumarate177$51,611
Stiolto RespimatTiotropium Br/Olodaterol Hcl84$48,945
JardianceEmpagliflozin60$48,919
Tadalafil28$44,789
Combivent RespimatIpratropium/Albuterol Sulfate66$37,973
JanuviaSitagliptin Phosphate28$23,455
OzempicSemaglutide21$22,970
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$22,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala$426$440,271647 claims
Boehringer IngelheimStiolto Respimat, Jardiance, Combivent Respimat, Spiriva Respimat$173$150,757226 claims
PfizerEliquis$13$81,368106 claims
AstraZenecaSymbicort, Breztri Aerosphere$266$74,398201 claims
MerckJanuvia$190$23,45528 claims
Novo NordiskOzempic$69$22,97021 claims
Johnson & JohnsonXarelto$40$21,74427 claims
AbbVieLinzess, Synthroid$16$15,32656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →